Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 18, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer

68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of 4.3 months (median 5.8 months from completing last...
January 15, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data on Friday, January 18th

NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology biotechnology company developing metabolically-based cancer therapeutics, today...
January 04, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Announces the Presentation of SM-88 Data at the 2019 ASCO Genitourinary Cancers Symposium

NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...
November 26, 2018 16:01 ET | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. to Present at the Piper Jaffray Healthcare Conference on November 28th

NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
November 26, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Announces the Presentation of Clinical Abstracts at the 2019 Gastrointestinal Cancers Symposium

NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...
November 20, 2018 16:45 ET | Source: Tyme Technologies, Inc.

Tyme Technologies, Inc. to Present at the Evercore ISI, HealthconX Conference on November 27th

NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
November 08, 2018 16:30 ET | Source: Tyme Technologies, Inc.

Tyme, Inc. to Present at the Stifel 2018 Healthcare Conference on November 13th

NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical stage biotechnology company developing cancer therapeutics for pancreatic, prostate and sarcoma tumors,...
November 05, 2018 08:33 ET | Source: Tyme Technologies, Inc.

Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019

SM-88 to be included in pivotal Precision Promise pancreatic cancer trial led by Pancreatic Cancer Action Network (PanCAN) expected to commence in the first half of 2019 Interim data for SM-88 from...
October 15, 2018 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer

NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc, (Nasdaq: TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...
October 10, 2018 06:00 ET | Source: Tyme Technologies, Inc.

Tyme’s SM-88 to be included in Pancreatic Cancer Action Network’s (PanCAN’s) Novel “Precision Promise(SM)” Adaptive Phase II/III Pancreatic Cancer Trial Platform

Innovative trial design intended to accelerate development of pancreatic cancer therapiesPotential pivotal pathway for SM-88 monotherapy in the second-line pancreatic cancer settingAlso planning to...